{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:02:42Z","timestamp":1784106162894,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11606-023-08027-4","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T21:32:42Z","timestamp":1674509562000},"page":"1871-1876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4789-4390","authenticated-orcid":false,"given":"Jessica J.","family":"Wyse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Morasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen F.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah S.","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Liberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis I.","family":"Lovejoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"8027_CR1","doi-asserted-by":"crossref","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. bmj. 2017;357.","DOI":"10.1136\/bmj.j1550"},{"key":"8027_CR2","unstructured":"National Academies of Sciences E and Medicine. Medications for opioid use disorder save lives. National Academies Press; 2019."},{"issue":"2","key":"8027_CR3","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622\u2013e1920622.","journal-title":"JAMA Netw Open."},{"issue":"3","key":"8027_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345.","journal-title":"Ann Intern Med."},{"issue":"3","key":"8027_CR5","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1037\/rmh0000187","volume":"45","author":"B Showers","year":"2021","unstructured":"Showers B, Dicken D, Smith JS, Hemlepp A. Medication for opioid use disorder in rural America: A review of the literature. J Rural Ment Health. 2021;45(3):184.","journal-title":"J Rural Ment Health."},{"issue":"1","key":"8027_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jrh.12307","volume":"35","author":"CHA Andrilla","year":"2019","unstructured":"Andrilla CHA, Moore TE, Patterson DG, Larson EH. Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health. 2019;35(1):108\u201312.","journal-title":"J Rural Health."},{"issue":"4","key":"8027_CR7","first-page":"300","volume":"323","author":"R Rubin","year":"2020","unstructured":"Rubin R Rural Veterans Less Likely to Get Medication for Opioid Use Disorder. JAMA. 2020;323(4):300\u2013300.","journal-title":"JAMA."},{"key":"8027_CR8","doi-asserted-by":"publisher","first-page":"107527","DOI":"10.1016\/j.drugalcdep.2019.06.029","volume":"204","author":"R Ghertner","year":"2019","unstructured":"Ghertner R US trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. Drug Alcohol Depend. 2019;204:107527.","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"8027_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jrh.12260","volume":"34","author":"EB Jones","year":"2018","unstructured":"Jones EB. Medication-Assisted Opioid Treatment Prescribers in Federally Qualified Health Centers: Capacity Lags in Rural Areas. J Rural Health. 2018;34(1):14\u201322.","journal-title":"J Rural Health."},{"issue":"3","key":"8027_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/08897077.2021.1975344","volume":"42","author":"PJ Joudrey","year":"2021","unstructured":"Joudrey PJ, Bart G, Brooner RK, Brown L, Dickson-Gomez J, Gordon A, et al. Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force report. Subst Abuse. 2021;42(3):245\u201354.","journal-title":"Subst Abuse."},{"key":"8027_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","volume":"93","author":"S Amiri","year":"2018","unstructured":"Amiri S, Lutz R, Soc\u00edas ME, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93:26\u201330.","journal-title":"J Subst Abuse Treat."},{"issue":"13","key":"8027_CR12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jama.2019.12562","volume":"322","author":"PJ Joudrey","year":"2019","unstructured":"Joudrey PJ, Edelman EJ, Wang EA. Drive Times to Opioid Treatment Programs in Urban and Rural Counties in 5 US States. JAMA. 2019;322(13):1310\u20132.","journal-title":"JAMA."},{"issue":"3","key":"8027_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/08897077.2020.1787299","volume":"41","author":"AJ Gordon","year":"2020","unstructured":"Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abuse. 2020;41(3):275\u201382.","journal-title":"Subst Abuse."},{"key":"8027_CR14","first-page":"1","volume":"3","author":"HJ Hagedorn","year":"2022","unstructured":"Hagedorn HJ, Gustavson AM, Ackland PE, Bangerter A, Bounthavong M, Clothier B, Harris AH, Kenny ME, Noorbaloochi S, Salameh HA, Gordon AJ. Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities. J Gen Intern Med. 2022; 3:1-9.","journal-title":"J Gen Intern Med."},{"issue":"12","key":"8027_CR15","doi-asserted-by":"publisher","first-page":"e2137238","DOI":"10.1001\/jamanetworkopen.2021.37238","volume":"4","author":"EJ Hawkins","year":"2021","unstructured":"Hawkins EJ, Malte CA, Gordon AJ, Williams EC, Hagedorn HJ, Drexler K, et al. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System. JAMA Netw Open. 2021;4(12):e2137238\u2013e2137238.","journal-title":"JAMA Netw Open."},{"issue":"4","key":"8027_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/ajhp\/zxaa405","volume":"78","author":"BM DeRonne","year":"2021","unstructured":"DeRonne BM, Wong KR, Schultz E, Jones E, Krebs EE. Implementation of a pharmacist care manager model to expand availability of medications for opioid use disorder. Am J Health Syst Pharm. 2021;78(4):354\u20139.","journal-title":"Am J Health Syst Pharm."},{"issue":"1","key":"8027_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-022-00312-7","volume":"17","author":"JJ Wyse","year":"2022","unstructured":"Wyse JJ, Mackey K, Kansagara D, Tuepker A, Gordon AJ, Korthuis PT, et al. Expanding access to medications for opioid use disorder through locally-initiated implementation. Addict Sci Clin Pract. 2022;17(1):1-1.","journal-title":"Addict Sci Clin Pract."},{"issue":"2","key":"8027_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/08897077.2018.1452327","volume":"39","author":"JJ Wyse","year":"2018","unstructured":"Wyse JJ, Gordon AJ, Dobscha SK, Morasco BJ, Tiffany E, Drexler K, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps. Subst Abuse. 2018;39(2):139\u201344.","journal-title":"Subst Abuse."},{"issue":"10","key":"8027_CR19","doi-asserted-by":"publisher","first-page":"e2236298","DOI":"10.1001\/jamanetworkopen.2022.36298","volume":"5","author":"MC Frost","year":"2022","unstructured":"Frost MC, Zhang L, Kim HM, Lin L (Allison). Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic. JAMA Netw Open. 2022;5(10):e2236298\u2013e2236298.","journal-title":"JAMA Netw Open."},{"issue":"1","key":"8027_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/jrh.12360","volume":"36","author":"AP Albanese","year":"2020","unstructured":"Albanese AP, Bope ET, Sanders KM, Bowman M. The VA MISSION Act of 2018: a potential game changer for rural GME expansion and veteran health care. J Rural Health. 2020;36(1):133.","journal-title":"J Rural Health."},{"issue":"5","key":"8027_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s11606-020-06339-3","volume":"36","author":"BA Howell","year":"2021","unstructured":"Howell BA, Abel EA, Park D, Edmond SN, Leisch LJ, Becker WC. Validity of incident opioid use disorder (OUD) diagnoses in administrative data: a chart verification study. J Gen Intern Med. 2021;36(5):1264\u201370.","journal-title":"J Gen Intern Med."},{"key":"8027_CR22","doi-asserted-by":"publisher","first-page":"108583","DOI":"10.1016\/j.drugalcdep.2021.108583","volume":"221","author":"P Lagisetty","year":"2021","unstructured":"Lagisetty P, Garpestad C, Larkin A, Macleod C, Antoku D, Slat S, et al. Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse. Drug Alcohol Depend. 2021;221:108583.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"8027_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.pain.2010.08.002","volume":"151","author":"BJ Morasco","year":"2010","unstructured":"Morasco BJ, Duckart JP, Carr TP, Deyo RA, Dobscha SK. Clinical characteristics of veterans prescribed high doses of opioid medications for chronic non-cancer pain. PAIN\u00ae. 2010;151(3):625\u201332.","journal-title":"PAIN\u00ae"},{"key":"8027_CR24","unstructured":"Center for Medicare & Medicaid Services. Access to Medications for Opioid Use Disorder (MOUD) Among Medicare Fee-for-Service Beneficiaries: Influence of CARES Act Implementation. [Internet]. 2022 Jan. Report No.: No. 29. Available from: https:\/\/www.cms.gov\/files\/document\/data-highlight-jan-2022-opiod.pdf"},{"issue":"1","key":"8027_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13722-021-00263-5","volume":"16","author":"EJ Hawkins","year":"2021","unstructured":"Hawkins EJ, Danner AN, Malte CA, Blanchard BE, Williams EC, Hagedorn HJ, et al. Clinical leaders and providers\u2019 perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs\u2019 facilities. Addict Sci Clin Pract. 2021;16(1):55.","journal-title":"Addict Sci Clin Pract."},{"key":"8027_CR26","unstructured":"Buprenorphine Prescribing for Opioid Use Disorder; VHA Notice 2022-02. Department of Veterans Affairs, Veterans health Administration; 2022."},{"key":"8027_CR27","doi-asserted-by":"crossref","unstructured":"Madras BK, Ahmad NJ, Wen J, Sharfstein J. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020;","DOI":"10.31478\/202004b"},{"key":"8027_CR28","doi-asserted-by":"publisher","first-page":"108449","DOI":"10.1016\/j.jsat.2021.108449","volume":"131","author":"S Brothers","year":"2021","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Subst Abuse Treat. 2021;131:108449.","journal-title":"J Subst Abuse Treat."},{"issue":"9","key":"8027_CR29","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamapsychiatry.2022.1776","volume":"79","author":"CM Jones","year":"2022","unstructured":"Jones CM, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. JAMA Psychiatry. 2022;79(9):932\u20134.","journal-title":"JAMA Psychiatry."},{"key":"8027_CR30","first-page":"1","volume":"20","author":"O Amram","year":"2021","unstructured":"Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021 20;1\u20138.","journal-title":"Am J Drug Alcohol Abuse."},{"key":"8027_CR31","doi-asserted-by":"publisher","first-page":"106603","DOI":"10.1016\/j.ypmed.2021.106603","volume":"152","author":"DT Moore","year":"2021","unstructured":"Moore DT, Wischik DL, Lazar CM, Vassallo GG, Rosen MI. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub. Prev Med. 2021;152:106603.","journal-title":"Prev Med."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-023-08027-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-023-08027-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-023-08027-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:32:49Z","timestamp":1744209169000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-023-08027-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["8027"],"URL":"https:\/\/doi.org\/10.1007\/s11606-023-08027-4","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no conflicts of interest to report.DisclaimerThe content is solely the responsibility of the authors and does not represent the official views of the Department of Veterans Affairs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}